Clearside reports Q3 net loss of $7.8M; OASIS trial shows positive durability for CLS-AX

Clearside Biomedical, Inc.

Q3 2022 net loss of $7.8M ($0.13/share) vs $4.9M loss in Q3 2021; revenue fell to $0.3M from $3.1M.
OASIS Phase 1/2a met primary safety endpoint; no serious adverse events in 27 wet AMD patients.
Cohorts 3/4: 88% injection-free to Month 5, 75% to Month 6; >90% reduction in treatment burden.
Company expects to initiate Phase 2 trial for CLS-AX in wet AMD in Q1 2023.
Entered royalty interest sale with HealthCare Royalty for up to $65M non-dilutive funding; cash $53.4M, runway into 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Clearside Biomedical, Inc. reported the third quarter ended September 30, 2022 results: revenue $0.3 million, net income $7.8 million, EPS $0.13 per share of common stock.

Period: the third quarter ended September 30, 2022
Revenue: $0.3 million
Net income: $7.8 million
EPS: $0.13 per share of common stock
Result: reported results

Exact text from the filing

Clearside’s license and other revenue for the third quarter of 2022 was $0.3 million

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023528

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.